A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough.

ABSTRACT:

Objective

Baclofen is a centrally acting γ-aminobutyric acid type B (GABA_B) receptor agonist which reduces gastro-oesophageal reflux and suppresses the cough reflex; however, central nervous system side-effects limit its use. Lesogaberan is a novel peripherally acting GABA_B agonist, but its effects on refractory chronic cough are unknown.

Design

We performed a single-centre, placebo-controlled, double-blind randomised crossover study in patients with chronic cough, refractory to the treatment of underlying conditions. Patients were randomised to treatment with lesogaberan 120 mg modified release twice daily or matched placebo for 2 weeks and then crossed over to the alternative therapy after a 2-week washout. The primary end-point was 24-h cough frequen

SUBMITTER: Badri H 

PROVIDER: S-EPMC8918934 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature